Research map: Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update

Back to the article

Papers in this map

  1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  2. BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guérin Delivery for High-risk Non–muscle-invasive Bladder Cancer · 2026 · Related
  3. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial · David A. Palma · 2020 · 1295 citations · Cited by this paper
  4. Radioligand Therapy (RLT) in France · 2026 · Related
  5. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer · Derya Tilki · 2024 · 354 citations · Cited by this paper
  6. Seeking a Credible Basis for Prostatic Obstruction as the Reversible Cause of Other Lower Urinary Tract Dysfunctions · 2026 · Related
  7. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial · Shankar Siva · 2018 · 325 citations · Cited by this paper
  8. Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer · 2026 · Related
  9. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials · Matthew Pierre Deek · 2022 · 257 citations · Cited by this paper
  10. Early-access Use of Radioligand Therapy in Prostate Cancer · 2026 · Related
  11. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study · Bastiaan M. Privé · 2021 · 101 citations · Cited by this paper
  12. Genitourinary Injury After Radiation Therapy: Understanding Burden of Disease and Evolving Therapeutic Advancements · 2026 · Related
  13. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome · Steffie M. B. Peters · 2021 · 92 citations · Cited by this paper
  14. Conceptualizing the “High” Bladder Neck – Anatomic Rabbit Hole or Functional Gold Mine? · 2026 · Related
  15. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial · Bastiaan M. Privé · 2020 · 45 citations · Cited by this paper
  16. Postvoided Residual/Bladder Emptying: A Mini Review · 2026 · Related
  17. 177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study · Amar Upadhyaya Kishan · 2025 · 29 citations · Cited by this paper
  18. Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial · 2026 · Related
  19. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study · Bastiaan M. Privé · 2026 · 16 citations · Cited by this paper
  20. Contemporary Prostate Cancer Intraprostatic Imaging Scores: A Practical and Hands-on Guide for Urologists · 2026 · Related
  21. 2387P 177Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE) · Bastiaan M. Privé · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)